Amgen/AstraZeneca’s Tezepelumab Cuts Asthma Exacerbations By 56%
Low Eosinophil Patients Have 39% Reduction, Supporting Broad Label
Executive Summary
Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics.